FIELD: organic chemistry.
SUBSTANCE: present invention refers to a compound of formula (I)
or its pharmaceutically acceptable salt. In formula (I), R2 is selected from -Cl, Br and -CN, R1 and R4 are independently selected from -H and -F, R631, R632, R641 and R642 are independently selected from -H, -F and C1-C3 alkyl, R651 and R652 are independently selected from H and C1-C3 alkyl, and at least one of R631, R632, R641, R642 and R652 does not represent -H or if all of R631, R632, R641, R642 and R652 are -H, R651 is not Me or Et. Also disclosed is a version of the compound, a pharmaceutical composition and use of said compounds.
EFFECT: invention discloses novel organic compounds which are related to indolamine-2,3-dioxygenase (IDO) inhibitors and can be used for preparing drugs for treating ovary by inhibiting IDO.
12 cl, 2 dwg, 2 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW SUBSTITUTED N-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE (IDO) | 2018 |
|
RU2765371C2 |
| NEW SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INDOLEAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE INHIBITORS | 2017 |
|
RU2741911C2 |
| IMINOUREA DERIVATIVES | 2018 |
|
RU2780118C2 |
| PYRIDOPYRIMIDINONE DERIVATIVES AND USE THEREOF AS AROMATIC HYDROCARBON RECEPTOR MODULATORS | 2021 |
|
RU2818954C1 |
| N3-ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | 2003 |
|
RU2300528C2 |
| SUBSTITUTED INDAZOLES SUITABLE FOR TREATING AND PREVENTING ALLERGIC AND/OR INFLAMMATORY DISEASES IN ANIMALS | 2017 |
|
RU2743170C2 |
| CAFFEIC ACID BIOLOGICALLY AVAILABLE FOR ORAL USE, ASSOCIATED WITH ANTITUMOUR MEDICINAL AGENTS | 2007 |
|
RU2456265C2 |
| SUBSTITUTED 2-METHYLIDEN-5-(PHENYLAMINO)-2,3-DIHYDROTIOPHEN-3-ONE FOR TREATMENT OF LEUKEMIAS WITH TRANSLOCATIONS OF MLL-GENE AND OTHER ONCOLOGICAL DISEASES | 2017 |
|
RU2656603C1 |
| BENZYLHYDROXIDE DERIVATIVES, PRODUCTION THEREOF AND THERAPEUTIC APPLICATION THEREOF | 2015 |
|
RU2704017C2 |
| EGFR INHIBITOR COMPOUNDS | 2017 |
|
RU2751341C2 |
